Dr Setareh Shamsili has resigned as a board member and chief medical officer of Ryvu Therapeutics effective August 31, 2021, the company said. “The reason for the resignation are personal reasons” .
During the transitional period, substantive support in the field of clinical trials in the form of additional consultations is to be provided to the company by prof. dr. n. med. Axel Glasmacher, who has been a member of the supervisory board since 2019.
“We would also like to express our gratitude to Setareh for the progress made in Ryvu’s clinical projects during her collaboration with the company, for expanding the clinical team and contributing to the company’s corporate development, and we wish her good luck in her future career. Axel is a key member of our supervisory board and brings over 25 years of experience in cancer drug development to the company. We are excited about the prospect of his greater involvement in the work of Ryvu, commented president Paweł Przewięźlikowski, quoted in the press release.